Dong-Gu Shin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dong-Gu Shin has a total of 317 co-authors. Here are the top co-authors by number of shared publications:
Bong Sup Shim
Cardiovascular Division, Internal Medicine, College of Medicine, Yeungnam University, Daegu, Korea
18 shared publicationsJong Seon Park
Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Korea
18 shared publicationsYoung Jo Kim
Cardiovascular Division, Internal Medicine, College of Medicine, Yeungnam University, Daegu, Korea
17 shared publications- Young Jo Kim
Yeungnam University Hospital, Daegu, Republic of Korea
17 shared publications Jong-Seon Park
Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea
14 shared publicationsChan-Hee Lee
Yeungnam University College of Medicine, Daegu, Korea
10 shared publications
Latest Publications
- Open Access
- 15 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (8) , 2887
Comparing the Efficacy of Carvedilol and Flecainide on the Treatment of Idiopathic Premature Ventricular Complexes from Ventricular Outflow Tract: A Multicenter, Randomized, Open-Label Pilot Study
The mechanism of premature ventricular complexes (PVC) occurring in the ventricular outflow tract (OT) is related to an intracellular calcium overload and delayed afterdepolarizations that lead to triggered activity. The guidelines recommend using beta-blockers and flecainide for idiopathic PVCs, but they also acknowledge the limited evidence supporting this recommendation. We conducted a multicenter, randomized, open-label pilot study comparing the effect of carvedilol and flecainide on OT PVC, which are widely used to treat this arrhythmia. Patients with a 24 h Holter recording a PVC burden ≥ 5%, which showed positive R waves in leads II, III, and aVF, and without structural heart disease were enrolled. They were randomly assigned to the carvedilol or flecainide group, and the maximum tolerated dose was administered for 12 weeks. A total of 103 participants completed the protocol: 51 with carvedilol and 52 with flecainide. After 12 weeks of treatment, the mean PVC burden significantly decreased in both groups: 20.3 ± 11.5 to 14.6 ± 10.8% with carvedilol (p < 0.0001) and 17.1 ± 9.9 to 6.6 ± 9.9% with flecainide (p < 0.0001). Both carvedilol and flecainide effectively suppressed OT PVCs in patients without structural heart disease, with flecainide showing a superior efficacy compared to carvedilol.
- 15 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (8) , 2887
Open AccessComparing the Efficacy of Carvedilol and Flecainide on the Treatment of Idiopathic Premature Ventricular Complexes from Ventricular Outflow Tract: A Multicenter, Randomized, Open-Label Pilot Study
The mechanism of premature ventricular complexes (PVC) occurring in the ventricular outflow tract (OT) is related to an intracellular calcium overload and delayed afterdepolarizations that lead to triggered activity. The guidelines recommend using beta-blockers and flecainide for idiopathic PVCs, but they also acknowledge the limited evidence supporting this recommendation. We conducted a multicenter, randomized, open-label pilot study comparing the effect of carvedilol and flecainide on OT PVC, which are widely used to treat this arrhythmia. Patients with a 24 h Holter recording a PVC burden ≥ 5%, which showed positive R waves in leads II, III, and aVF, and without structural heart disease were enrolled. They were randomly assigned to the carvedilol or flecainide group, and the maximum tolerated dose was administered for 12 weeks. A total of 103 participants completed the protocol: 51 with carvedilol and 52 with flecainide. After 12 weeks of treatment, the mean PVC burden significantly decreased in both groups: 20.3 ± 11.5 to 14.6 ± 10.8% with carvedilol (p < 0.0001) and 17.1 ± 9.9 to 6.6 ± 9.9% with flecainide (p < 0.0001). Both carvedilol and flecainide effectively suppressed OT PVCs in patients without structural heart disease, with flecainide showing a superior efficacy compared to carvedilol.
- Open Access
- 5 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (31) , e29949
Surface ECG–based complexity parameters for predicting outcomes of catheter ablation for nonparoxysmal atrial fibrillation: efficacy of fibrillatory wave amplitude
Catheter ablation (CA) is a well-established therapy for rhythm control in atrial fibrillation (AF). However, CA outcomes for persistent AF remain unsatisfactory because of the high recurrence rate despite time-consuming efforts and the latest ablation technology. Therefore, the selection of good responders to CA is necessary. Surface electrocardiography (sECG)-based complexity parameters were tested for the predictive ability of procedural termination failure during CA and late recurrence of atrial arrhythmias (AA) after CA. A total of 130 patients with nonparoxysmal AF who underwent CA for the first time were investigated. A 10-second sECG of 4 leads (leads I, II, V1, and V6) was analyzed to compute the fibrillatory wave amplitude (FWA), dominant frequency (DF), spectral entropy (SE), organization index (OI), and sample entropy (SampEn). The study endpoints were procedural termination failure during CA and late (≥1 year) AA recurrence after CA. In the multivariate analysis, FWA in lead V1 and DF in lead I were independent predictors of successful AF termination during CA (P <.05). The optimal cut-off values for FWA in lead V1 and DF in lead I were 60.38 μV (area under the curve [AUC], 0.672; P = .001) and 5.7 Hz (AUC, 0.630; P = .016), respectively. The combination of FWA of lead V1 and DF of lead I had a more powerful odds ratio for predicting procedural termination failure (OR, 8.542; 95% CI, 2.938–28.834; P < .001). FWA in lead V1 was the only independent predictor of late recurrence after CA. The cut-off value is 65.73 μV which was 0.634 of the AUC (P = .009). These sECG parameters, FWA in lead V1 and DF in lead I, predicted AF termination by CA in patients with nonparoxysmal AF. In particular, FWA in lead V1 was an independent predictor of late recurrence of AA after CA.
- 5 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (31) , e29949
Open AccessSurface ECG–based complexity parameters for predicting outcomes of catheter ablation for nonparoxysmal atrial fibrillation: efficacy of fibrillatory wave amplitude
Catheter ablation (CA) is a well-established therapy for rhythm control in atrial fibrillation (AF). However, CA outcomes for persistent AF remain unsatisfactory because of the high recurrence rate despite time-consuming efforts and the latest ablation technology. Therefore, the selection of good responders to CA is necessary. Surface electrocardiography (sECG)-based complexity parameters were tested for the predictive ability of procedural termination failure during CA and late recurrence of atrial arrhythmias (AA) after CA. A total of 130 patients with nonparoxysmal AF who underwent CA for the first time were investigated. A 10-second sECG of 4 leads (leads I, II, V1, and V6) was analyzed to compute the fibrillatory wave amplitude (FWA), dominant frequency (DF), spectral entropy (SE), organization index (OI), and sample entropy (SampEn). The study endpoints were procedural termination failure during CA and late (≥1 year) AA recurrence after CA. In the multivariate analysis, FWA in lead V1 and DF in lead I were independent predictors of successful AF termination during CA (P <.05). The optimal cut-off values for FWA in lead V1 and DF in lead I were 60.38 μV (area under the curve [AUC], 0.672; P = .001) and 5.7 Hz (AUC, 0.630; P = .016), respectively. The combination of FWA of lead V1 and DF of lead I had a more powerful odds ratio for predicting procedural termination failure (OR, 8.542; 95% CI, 2.938–28.834; P < .001). FWA in lead V1 was the only independent predictor of late recurrence after CA. The cut-off value is 65.73 μV which was 0.634 of the AUC (P = .009). These sECG parameters, FWA in lead V1 and DF in lead I, predicted AF termination by CA in patients with nonparoxysmal AF. In particular, FWA in lead V1 was an independent predictor of late recurrence of AA after CA.
- Open Access
- 1 January 2022
- Published by XMLink in Yonsei Medical Journal
- Vol. 63 (3) , 211-219
Long-Term Safety and Efficacy of Prolonged Dual Antiplatelet Therapy according to Baseline Anemia after Percutaneous Coronary Intervention
Kim HT, et al. Yonsei Med J. 2022 Mar;63(3):211-219. https://doi.org/10.3349/ymj.2022.63.3.211
- 1 January 2022
- Published by XMLink in Yonsei Medical Journal
- Vol. 63 (3) , 211-219
Open AccessLong-Term Safety and Efficacy of Prolonged Dual Antiplatelet Therapy according to Baseline Anemia after Percutaneous Coronary Intervention
Kim HT, et al. Yonsei Med J. 2022 Mar;63(3):211-219. https://doi.org/10.3349/ymj.2022.63.3.211
- Open Access
- 1 January 2021
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 51 (10) , 851-862
Electrocardiographic Manifestations in Patients with COVID-19: Daegu in South Korea
Korean Circulation Journal 대한심장학회지 순환기 Bae HJ, et al. Korean Circ J. 2021 Jul;51:e98. https://doi.org/10.4070/kcj.2021.0116
- 1 January 2021
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 51 (10) , 851-862
Open AccessElectrocardiographic Manifestations in Patients with COVID-19: Daegu in South Korea
Korean Circulation Journal 대한심장학회지 순환기 Bae HJ, et al. Korean Circ J. 2021 Jul;51:e98. https://doi.org/10.4070/kcj.2021.0116
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (9) , e49
Clinical Impact of Implantable Cardioverter-Defibrillator Therapy and Mortality Prediction Model for Effective Primary Prevention in Korean Patients
Bae MH, et al. J Korean Med Sci. 2020 Jan;35(9):e49. https://doi.org/10.3346/jkms.2020.35.e49
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (9) , e49
Open AccessClinical Impact of Implantable Cardioverter-Defibrillator Therapy and Mortality Prediction Model for Effective Primary Prevention in Korean Patients
Bae MH, et al. J Korean Med Sci. 2020 Jan;35(9):e49. https://doi.org/10.3346/jkms.2020.35.e49
- 1 April 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 280, 69-73
Rationale, design, and endpoints of the ‘DEvice-Detected CArdiac Tachyarrhythmic Events and Sleep-disordered Breathing (DEDiCATES)’ study: Prospective multicenter observational study of device-detected tachyarrhythmia and sleep-disordered breathing
- 1 April 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 280, 69-73
Rationale, design, and endpoints of the ‘DEvice-Detected CArdiac Tachyarrhythmic Events and Sleep-disordered Breathing (DEDiCATES)’ study: Prospective multicenter observational study of device-detected tachyarrhythmia and sleep-disordered breathing
- 1 May 2018
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 27 (5) , 576-587
Normative Values of Short-Term Heart Rate Variability Parameters in Koreans and Their Clinical Value for the Prediction of Mortality
- 1 May 2018
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 27 (5) , 576-587
Normative Values of Short-Term Heart Rate Variability Parameters in Koreans and Their Clinical Value for the Prediction of Mortality
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (49) , e323
Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II
Oh S, et al. J Korean Med Sci. 2018 Nov;33(49):e323. https://doi.org/10.3346/jkms.2018.33.e323
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (49) , e323
Open AccessQuality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II
Oh S, et al. J Korean Med Sci. 2018 Nov;33(49):e323. https://doi.org/10.3346/jkms.2018.33.e323
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e108
Contributing factors for the short-term progression of carotid plaque and its correlation with clinical outcomes
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e108
Contributing factors for the short-term progression of carotid plaque and its correlation with clinical outcomes
- 28 March 2017
- Published by XMLink in International Journal of Arrhythmia
- Vol. 18 (1) , 16-26
The Impact of the CHA2DS2-VASc Score on Recurrence of Atrial Fibrillation after a Single Catheter Ablation and Atrial Remodeling in Patients with Non-Valvular Atrial Fibrillation
Values are presented as mean±standard deviation or number (%).
- 28 March 2017
- Published by XMLink in International Journal of Arrhythmia
- Vol. 18 (1) , 16-26
The Impact of the CHA2DS2-VASc Score on Recurrence of Atrial Fibrillation after a Single Catheter Ablation and Atrial Remodeling in Patients with Non-Valvular Atrial Fibrillation
Values are presented as mean±standard deviation or number (%).